EXPRESS MAIL NO. EV449556656US

3-29-59 Emore

## **TRANSMITTAL FORM**

(To be used for all correspondence after initial filing)

Application Number	09/685,830
Filing Date	October 9, 2000
First Named Inventor	Alexander Gaiger
Art Unit	1644
Examiner Name	Ronald B. Schwadron
Attorney Docket No.	210121.465C3

	ENC	LOSURES (check all that app	<u> </u>
Fee Transmittal for Fee Attached Amendment/Res After Final Affidavits/ded Extension of Tim Express Abandon Request Third Supplement Information Discles Statement; Form 3 Cited Reference Certified Copy of Document(s) Response to Misunder 37 C.F.R. Response to Mis Parts/Incomplete	Form d sponse claration(s) ne Request nment ntal losure n PTO-1449 ces f Priority ssing Parts 1.52 or 1.53 ssing	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer	CD(s), Number of CD(s)  After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Additional Enclosure(s) (please identify below):
Remarks			
<u>IXOMANO</u>			
	SIGNATURE	OF APPLICANT, ATTORNEY,	OR AGENT
Individual Name Julie A. Urvat Reg. No. 50,4		, Ph.D., Patent Agent 1	Customer Number 00500
Signature (	July	Uwat	
Date March 26, 200			
	CERTIF	ICATE OF TRANSMICSION (NA	
with the United State	this correspond es Postal Servi	ICATE OF TRANSMISSION/MA lence is being facsimile transmitt ce with sufficient postage as first atents, P.O. Box 1450, Alexandr	ted to the USPTO or deposited class mail in an envelope
Typed or printed nar	me	· ·	
Signature			Date:
	equired by 37 CFR 1.5. To	he information is required to obtain or retain a benefit	

process) an apprication. Cumindentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. \469049

/	OIPE	7
/ D	MAR 2 6	DOK S
ES .	CE TRADE	Ap

# FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27.

TOTAL AMOUNT OF PAYMENT

180.00

	Complete if Known				
Application Number	09/685,830				
Filing Date	October 9, 2000				
First Named Inventor	Alexander Gaiger				
Examiner Name	Ronald B. Schwadron				
Art Unit	1644				
Attorney Docket No.	210121.465C3				

		ME	THOD C	F PAYMENT_
X Pay	ment Encl	osed:		
	Г	Credit c	ard 📗	Money Order Other
٠ -	osit Accou	int:		
A	eposit ccount umber	19-10	90	
A	eposit ccount ame	Seed PLLC	Intelled	ctual Property Law Group
The Dire	ector is au	thorized	to (che	ck all that apply)
ΙП	Charge fee	e(s) indicat	ed below	Credit any overpayments
l H	_			
l∐	Charge an	y additiona	al fee(s)	during the pendency of this application
	Charge fee	e(s) indicat	ed below	v, except for the filing fee
lä	-			. ,
<u> </u>	Charge an	-		
to the abo	ove-identifi	ed deposit	account	•
		F	EE CAL	CULATION
1. BAS	SIC FILING			
Large E		mall Entit	v	
Fee	Fee(\$)		<u>v</u> ee(\$)	Fee Description Fee
Code		Code	(+)	Paid
1001	770	2001	385	Utility filing fee
1002	340	2002	170	Design filing fee
1003	530	2003	265	Plant filing fee
1004	770	2004	385	Reissue filing fee
1005	160	2005	80	Provisional filing fee
				SUBTOTAL (1) (\$)
2. <u>EXTE</u>	RA CLAIM	FEES FC	R UTIL	ITY AND REISSUE
				Fee Extra from Fee
				Claims below Paid
Total Cla	ims		-** =	* =
Independe	ent -	=		
Claims				
Multiple Depender	nt			=
	Entity	Small E	ntity	
Fee	Fee	Fee	Fee	For Boardatton
Code	(\$)	Code	(\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims ove original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent
			CLID	
			SUB	TOTAL (2) (\$)
**or num	har araviau	hy poid if a	rootor E	or Baissuos, son aboun

<u> </u>			FEE CA	ALCULATION (continued)		
3. ADDI	TIONAL	FEES				
Large Entity Small						
Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid	
1051	130	2051	65	Surcharge - late filing fee or oath		
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.		
1053	130	1053	130	Non-English specification		
1812	2520	1812	2520	For filing a request for ex parte reexamination		
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action		
1805	1840*	1805	1840*	Requesting publication of SIR after Examiner action		
1251	110	2251	55	Extension for reply within first month		
1252	420	2252	210	Extension for reply within second month		
1253	950	2253	475	Extension for reply within third month		
1254	1480	2254	740	Extension for reply within fourth month		
1255	2010	2255	1005	Extension for reply within fifth month		
1401	330	2401	165	Notice of Appeal		
1402	330	2402	165	Filing a brief in support of an appeal		
1403	290	2403	145	Request for oral hearing		
1451	1510	1451	1510	Petition to institute a public use proceeding		
1452	110	2452	55	Petition to revive – unavoidable		
1453	1330	2453	665	Petition to revive – unintentional		
1501	1330	2501	665	Utility issue fee (or reissue)		
1502	480	2502	240	Design issue fee		
1503	640	2503	320	Plant issue fee		
1460	130	1460	130	Petitions to the Commissioner		
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)		
1806	180	1806	180	Submission of Information Disclosure Stmt		
8021	40	8021	40	Recording each patent assignment per property (times number of properties)		
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))		
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))		
1801	770	2801	385	Request for Continued Examination (RCE)		
1802	900	1802	900	Request for expedited examination of a design application		
Other fee	(specify	)				
*Reduce	d by Bas	sic Filing	Fee Pa	sid SUBTOTAL (3) (\$) 180	.00	

	SUBMITTED BY				Customer Number
Name (Print/Type)	Julie A. Urvater, Ph.D., Patent Agent		ation No. y/Agent)	50,461	Customer Number
Signature	Culie 1) svat	Date	March	26, 2004	00500

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application of confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions/for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313/1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



#### EXPRESS MAIL NO. EV449556656US -

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicants** 

: Alexander Gaiger et al.

Application No.

09/685,830

Filed

October 9, 2000

For

COMPOSITIONS AND METHODS FOR WT1 SPECIFIC

**IMMUNOTHERAPY** 

Examiner

Ronald B. Schwadron

Art Unit

1644

Docket No.

210121.465C3

Date

March 26, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

#### Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

03/29/2004 KBETEMA1 00000119 09685830

01 FC:1806

180.00 OP

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

A fee of \$180 is submitted in accordance with 37 C.F.R. § 1.97(c). The Director is authorized to charge any other fees which may be required, or credit any overpayment to Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Julie A. Urvater, Ph.D., Patent Agent

Registration No. 50,461

JAU:ljt

MAR 2 6 2004

**Enclosures:** 

Postcard Check for \$180 Transmittal Form Fee Transmittal Form (+1) Form PTO-1449 Cited References (3)

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031

\469051

_E	<b>XPR</b>	₽	Ş	M
F	OM P	то	-14	49 4
(1	REV.7-8	30)	٠.	
	MAR	2	в	M
À	• •			O

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 210121.465C3

APPLICATION NO. 09/685,830

#HIRD SUPPLEMENTAL
#TION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Alexander Gaiger et al.

FILING DATE

APPLICANTS

GROUP ART UNIT

October 9, 2000

1644

				October 7, 2000	110	<del>'.'</del>		
			U.S	. PATENT DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING IF APPRO	
	AA	6,096,313	08/01/00	Jäger et al.	424	184.1		
	AB							·
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	Al							
	AJ							
			FORE	IGN PATENT DOCUMENTS		<b>!-</b>	1	
		DOCUMENT NUMBER	DATE	COUNTR	Y		TRANSI	ATION NO
	AK							
•	AL							
	AM					<del></del>		
•	AN							
	AO							
		ОТН	ER PRIOR A	$\Delta  extbf{RT}$ (Including Author, Title, Date, Pertine	ent Pages, Etc.)		1	
	AP	Boon, T., "T	umor Antigo	ens Recognized By Cytolytic Tapy," Int. J. Cancer 54: 177-18	Lymphocyte	s: Present	Perspe	ctive
	AQ	Oka, Y. et al	Oka, Y. et al., "Wilms Tumor Gene Peptide–Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis."					

•	AP	Boon, T., "Tumor Antigens Recognized By Cytolytic T Lymphocytes: Present Perspectives
	for Specific Immunotherapy," Int. J. Cancer 54: 177-180, 1993.	
	AQ	Oka, Y. et al., "Wilms Tumor Gene Peptide–Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis,"
		International Journal of Hematology 78: 56-61, 2003.
	AR	

**EXAMINER** 

DATE CONSIDERED

\* EXAMINER:

Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).